Archives
-
Lipid Nanoparticles in Cancer Immunotherapy
2026-10-01
This 2025 review explains how lipid nanoparticles can address degradation, cellular uptake, biodistribution, and toxicity barriers in nucleic acid cancer immunotherapy. Its central contribution is an integrated framework linking cargo selection, nanoparticle properties, immune-cell delivery, and translational limitations rather than introducing a new formulation.
-
Drosophila Keap1–Lamin Dm0 in Nuclear Architecture
2026-10-01
Carlson and colleagues identify a molecular and genetic relationship between Drosophila Keap1 and the B-type lamin Dm0, extending Keap1 biology beyond oxidative and xenobiotic transcriptional responses. Their results connect dKeap1 mis-regulation with lamin redistribution, altered heterochromatin-associated H3K9me2 patterns, nuclear-lamina defects, and developmental viability.
-
Deracoxib and Canine Osteosarcoma Cell Viability
2026-09-30
Royals and colleagues compared Deracoxib with piroxicam in three canine osteosarcoma cell lines and a fibroblast control, finding stronger and more consistent viability inhibition with Deracoxib. The study also showed that reduced viability was not accompanied by detectable DNA fragmentation, separating cytotoxicity from demonstrated apoptosis under the tested conditions.
-
Thymoquinone Workflow for Cardiotoxicity Research
2026-09-30
Build a translational workflow around Thymoquinone to connect cardiac function, oxidative stress, ferroptosis, and mitochondrial injury. The approach combines literature-backed mouse dosing with flexible cell-based optimization, helping researchers distinguish genuine cardioprotection from solvent, assay, or exposure artifacts.
-
Indole-3-pyruvic acid: Applied Research Workflows
2026-09-29
Indole-3-pyruvic acid (IPA) links auxin pathway control with AhR-focused immune assays. This workflow-led guide shows how to handle IPA, select controls, reproduce the rheumatoid arthritis model logic, and troubleshoot plant, fungal, and mammalian experiments.
-
Salvianolic Acid B, LH2, and Pulmonary Fibrosis
2026-09-29
The reference study identifies Salvianolic acid B (Dan Shen Suan B) as a candidate antifibrotic agent that reduces LH2-associated collagen cross-linking and pulmonary fibrotic remodeling. Its integrated cellular and tissue-level design connects LH2 expression with epithelial–mesenchymal transition, fibroblast activation, Wnt/β-catenin signaling, collagen deposition, and lung architecture, while leaving important questions about direct target engagement and clinical translation.
-
Axitinib (AG 013736) Research Workflows
2026-09-28
Build more informative angiogenesis and cancer models with Axitinib (AG 013736), from VEGF-pathway phosphorylation assays to endothelial survival and xenograft studies. A two-metric response strategy helps distinguish cytostatic effects from actual cell killing, improving interpretation of treatment timing and potency.
-
Mdivi-1 for Reproducible Apoptosis Assays
2026-09-28
Practical guidance for using Mdivi-1 (SKU A4472) in cell viability, apoptosis, and mitochondrial dynamics research. Learn how to select compatible readouts, handle the DMSO-soluble compound, interpret results cautiously, and assess supplier options without mistaking a pharmacological response for proof of target specificity.
-
8-DY547-cGMP: A Fluorescent Assay Strategy
2026-09-26
Learn how 8-DY547-cGMP can support fluorescent studies of cyclic GMP, what to validate before interpreting an assay, and why a recent CA2 perineuronal-net study offers a useful lesson in matching measurements to biological questions.
-
Measuring Drug Response Beyond a Single Viability Score
2026-09-25
Hannah R. Schwartz’s dissertation highlights a basic but consequential distinction in cancer pharmacology: relative viability combines proliferative arrest and cell loss, whereas fractional viability is intended to measure cell killing. Its central finding—that drugs can affect both processes in different proportions and on different timelines—supports using complementary readouts when interpreting in vitro responses.
-
N3-kethoxal for Mapping DNA–Protein Interfaces
2026-09-25
N3-kethoxal offers a way to map accessible guanines and add a bioorthogonal handle to nucleic acids. This article connects that chemistry to research on NET–thrombin binding, explaining what the findings enable—and what the probe cannot establish on its own.
-
XPO1 Inhibition Suppresses Wnt Signaling in CRC
2026-09-24
A bioRxiv study reports that the XPO1 inhibitor Eltanexor (KPT-8602) reduces colorectal tumorigenesis in Apcmin/+ mice and links this effect to lower Wnt/β-catenin activity and COX-2 expression. Its cell, organoid, and mouse-model findings support further investigation of nuclear export inhibition as a chemoprevention strategy, while leaving important questions about mechanism, dosing, and human relevance.
-
MK-1775: Wee1 Kinase Inhibitor Evidence Guide
2026-09-24
MK-1775 is a potent, ATP-competitive Wee1 kinase inhibitor reported to inhibit Wee1 at 5.2 nM in a cell-free kinase assay. Its research rationale is G2 DNA damage checkpoint abrogation and potential sensitization of p53-deficient tumor cells to DNA-damaging agents; the available product data do not establish clinical efficacy.
-
GSK J4 HCl for H3K27 and CXCL10 Studies
2026-09-23
Use GSK J4 HCl to test whether JMJD3-dependent H3K27 demethylation contributes to inflammatory gene expression, with promoter-level assays that connect chromatin state to CXCL10 output. The workflow distinguishes this perturbation from the EZH2-driven mechanism reported in decidual cells and includes practical controls for dosing, viability, and interpretation.
-
β-Galactosidase Reporter Assay Kit Guide
2026-09-23
The β-Galactosidase Reporter Assay Kit provides a practical route for quantifying promoter-driven gene expression. This guide connects reporter assay design with new cross-kingdom promoter research and explains how to interpret measurements across Escherichia coli and Saccharomyces cerevisiae.